Akers Biosciences (AKER) Receives European Patent Covering Breath Ketone Detector
- Wall Street dips as investors turn defensive
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- Qualcomm (QCOM) Thrashed as Apple (AAPL) Lawsuit Threatens Licensing Business Model
- McDonald's (MCD) Tops Q4 EPS by 3c
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Akers Biosciences, Inc. (Nasdaq: AKER) announces that the European Patent Office has issued a patent covering the Company's Breath Ketone Detector (EP 2684025) (the "Patent"), the Company's single-use, non-invasive, breath device to rapidly monitor ketone levels. Akers Bio was granted U.S. patent protection covering the same technology in 2014.
The Patent protects both the methods and devices related to the Breath Ketone Detector. The Breath Ketone Detector was developed utilizing Akers Bio's proprietary MPC Biosensor Technology platform which facilitates the rapid identification of medical or metabolic conditions through biomarkers in exhaled breath condensate.
Ketones are acids which have the potential to build up in the body causing a condition referred to as ketosis. An extreme form of this condition is a life-threatening medical emergency called ketoacidosis. At-risk populations for this severe form of ketosis include those with diabetes, and people who subscribe to restrictive ketogenic diets for epilepsy management or to obtain aggressive weight loss results.
The Company's Breath Ketone Detector technology is a first-in-class device that detects the presence of ketones in a person's breath condensate. Ketones are present in the blood and breath before they can be detected in urine, making this a highly desirable screening method -- both in terms of cost and comfort -- when compared to invasive blood tests.
Akers Bio has developed three applications to date for the Breath Ketone Detector which will be marketed as BreathScan® DKA -- for real-time monitoring and diagnostic use by diabetics (subject to regulatory clearance); BreathScan KetoChek™ -- part of the Akers Wellness line, enabling users to track and monitor their ketone levels in conjunction with a quantitative reading device connected to a smartphone app; and METRON® -- a consumer-focused qualitative version from the Akers Wellness line aimed at people interested weight loss management and fitness.
"Having robust protection over our intellectual property is of paramount importance for safeguarding the value of our inventions. We are delighted to have been awarded this Patent which offers broad coverage and has been some years in the making," said Raymond F. Akers, Jr., Ph.D., Co-founder and Chief Scientific Director.
"Achieving patent protection in the key territories of the U.S. and Europe is very significant for the Breath Ketone Detector technology because of the enormous target markets of diabetes and health and wellness that we are positioning the tests for," continued Dr. Akers.
"The technology has a large number of potential mass-market applications, including within health and wellness, but in particular, we believe the ability to help Type 1 and some Type 2 diabetics monitor their ketone levels in a non-invasive, convenient format will be a significant advancement in the management of a disease that affects hundreds of millions of people worldwide," added Dr. Akers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Endo Int'l (ENDP) Agrees to Abandon Noncompetitive Pay-for-Delay in Settlement with FTC
- Silgan (SLGN) to Acquire WestRock's (WRK) Specialty Closures and Dispensing Systems Business for $1.03B
- Theravance Biopharma (TBPH) Reports Interim Data from TOUR Study in Oral Presentation at SCCM
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!